Abstract
Following the expansion of the World Health Organization's guidelines on eligibility for the seasonal malaria chemoprevention (SMC), the government of Kenya prepared to implement SMC for a first time in Turkana Central Sub-County in 2024. To inform design of SMC, we conducted a baseline qualitative and quantitative study. Using a stratified cluster sampling approach, we enrolled 198 households with children 6 months - 5 years old, and tested all individuals one year and older using a Rapid Diagnostic Test (RDT) and polymerase chain reaction (PCR). We carried out 82 key informant interviews, 31 focus group discussions with community health workers, elders, and caretakers of children, and 60 In-depth interviews with caretakers. Malaria prevalence was 21% [9%-42%] as reported by RDT and 21% [11%-38%] by PCR. Prevalence varied across villages, with the highest positivity of 73% by PCR. While SMC was perceived positively, challenges identified included physical access (households far from village centers, pastoralists, children living in the streets); stigma (children living with disabilities, households with members struggling with alcohol use); and acceptability (traditionalists, highly educated households). This study found that while malaria burden is high in the region, SMC may be a feasible approach to reduce its burden and transmission. However, implementation of SMC should be tailored, with a combination of centralized distribution supplemented by door-to-door and outreach to pastoralists and people in the interior. Using existing grassroots structures, such as Tree of Men and religious and group leaders, and intensive mobilization will be critical for success of this intervention.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Catholic Relief Services.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Research Ethics Committee of Moi University gave ethical approval for this work. Institutional Review Board of Duke University gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data produced in the present study are available upon reasonable request to the authors.
